Ponte Biosciences

Ponte Biosciences is an early-stage biotech company developing a novel bioartificial liver system for acute liver failure, a condition with high mortality and limited treatment options. Its foundational technology, the SRBAL System, originated from the Mayo Clinic and is designed to support patients in intensive care. The company's mission extends beyond the device itself to solving the broader supply constraint of functional human hepatocytes, which could enable applications in cell therapy, gene therapy, and toxicology research. As a preclinical, private company, Ponte is positioned at the intersection of tissue engineering and critical care medicine.

Spheroid Reservoir Bioartificial Liver (SRBAL) System utilizing metabolically active primary human hepatocytes in a 3D spheroid format for extracorporeal liver support.

Competes in the artificial/organ support space, historically including devices like the HepatAssist and ELAD systems, which faced clinical challenges. Current standard of care is supportive care and transplantation. Potential future competitors include other bioengineering approaches (e.g., stem cell-derived therapies, xenogeneic hepatocytes) and improved pharmacological support.